⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
P7C3 (NAMPT Activator)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-16 — Endothelial C/EBPβ/AEP pathway drives vascular deterioration and systemic aging.: cross-connection with aep-inhibitors: Both target the NAMPT/NAD-salvage axis but at different points: AEP inhibition (CP#11A) blocks proteolytic destruction of NAMPT in endothelium, while P7C3 pharmacologically activates residual NAMPT — convergent rationale for preserving NAD via NAMPT rather than precursor loading. (novelty: 4)
- 2026-09-20 — Preliminary findings on the enhancement of skeletal muscle structure and function in aged male mice by P7C3 activation of nicotinamide phosphoribosyl transferase (NAMPT).: Aged male mouse study (2-year-old mice, 10 mg/kg P7C3 daily × 4 weeks vs DMSO): improved ex vivo EDL and soleus contractility, shifted tibialis anterior myofiber CSA toward larger fibers, elevated Nampt and p-Akt/Akt, and preserved grip strength — first preclinical signal that pharmacologic NAMPT activation improves aged skeletal muscle structure and function. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
Preliminary findings on the enhancement of skeletal muscle structure and function in aged male mice by P7C3 activation of nicotinamide phosphoribosyl transferase (NAMPT).
20-sep-2026
novelty 3
per-area 3
strengthens